Mark A. Exley

About

Mark A. Exley, Ph.D., is a translational immunologist and biotech R&D executive focused on cancer immunotherapy and cell therapy. He became Chief Scientific Officer of LIfT BioSciences in April 2025 after serving as Chief Scientific Officer of Imvax, and public profiles also place him in senior immunology roles connected to MiNK Therapeutics and earlier academic appointments at Harvard Medical School and the University of Manchester. His public profile is strongest as a scientific/operator figure in biotech rather than as an investor or fund manager.

Areas of interest